Synapse - Andrew Zelenetz

Search Within

Andrew D Zelenetz

Results (785)

Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)

Meeting Abstract

Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S.; Qin, J.; Malhotra, S.; Yahalom, J.; Moskowitz, C. H.
Blood (2002)

Fulltext@MSK | Save

Autologous transplantation (ASCT) with total body irradiation (TBI) based conditioning appears superior to chemotherapy only (Non-TBI) conditioning for patients with relapsed or primary refractory chemosensitive (CS) diffuse large B-cell lymphoma (DLBCL) who have no extranodal sits (ENS) of disease (dz)

Meeting Abstract

Kewalramani, T.; Moskowitz, C. H.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Nimer, S. D.
Blood (2002)

Fulltext@MSK | Save

Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [Bexxar (R)]

Meeting Abstract

Zelenetz, A. D.; Saleh, M.; Vose, J.; Younes, A.; Kaminski, M. S.
Blood (2002)

Fulltext@MSK | Save

Bexxar (R) radioimmunotherapy produces a substantial number of durable complete responses in patents with multiply relapsed or refractory low grade or transformed love grade non-Hodgkin's lymphoma

Meeting Abstract

Kaminski, M. S.; Zelenetz, A.; Leonard, J.; Saleh, M.; Jain, V.
Blood (2002)

Fulltext@MSK | Save

Characteristics of patients with relapsed and refractory low grade non-Hodgkin's lymphoma who sustained durable responses following treatment with tositumomab and iodine I 131 tositumomab (Bexxar (R))

Meeting Abstract

Gregory, S. A.; Kaminski, M. S.; Zelenetz, A. D.; Jain, V.
Blood (2002)

Fulltext@MSK | Save

Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)

Meeting Abstract

O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
Blood (2002)

Fulltext@MSK | Save

REL is not the functional target gene within the 2p12-16 amplicon in diffuse large B-cell lymphoma

Meeting Abstract

Houldsworth, J.; Olshen, A. B.; Cattoretti, G.; Donnelly, G.; Teruya-Feldstein, J.; Qin, J.; Shen, Y.; Zelenetz, A. D.; Chaganti, R. S. K.
Blood (2002)

Fulltext@MSK | Save

H. pylori-independent MALT lymphoma of the stomach: Excellent outcome with radiation alone

Meeting Abstract

Yahalom, J.; Portlock, C. S.; Gonzales, M.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Zelenetz, A. D.
Blood (2002)

Fulltext@MSK | Save

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice

Journal Article

Roberts, W. K.; Livingston, P. O.; Agus, D. B.; Pinilla-Ibarz, J.; Zelenetz, A.; Scheinberg, D. A.
Blood (2002)

Fulltext@MSK | Save

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation

Journal Article

Pan, D.; Moskowitz, C. H.; Zelenetz, A. D.; Straus, D.; Kewalaramani, T.; Noy, A.; Qin, J.; Teruya-Feldstein, J.; Portlock, C. S.
The Cancer Journal (2002)

Fulltext@MSK | Save